Brief: Guard Therapeutics Reports Positive Results From Phase 1B Study

Disruptive Pharma AB (publ)

15/09/2021 06:35

Sept 15 (Reuters) - Guard Therapeutics International AB
(publ)  GUARD.ST :
    * GUARD THERAPEUTICS REPORTS POSITIVE RESULTS FROM PHASE 1B
STUDY
    * STUDY FULFILLED ITS PRIMARY OBJECTIVE - TO CONFIRM
ROSGARD'S
FAVOURABLE SAFETY AND TOLERABILITY PROFILE IN PATIENT POPULATION
FOR WHICH TREATMENT IS INITIALLY INTENDED
    * ANALYSES OF SEVERAL WELL-ESTABLISHED BIOMARKERS INDICATE
ROSGARD
POTENTIALLY HAS ABILITY TO PROTECT KIDNEY CELLS FROM INJURY
ASSOCIATED WITH HEART SURGERY
    * HAS DECIDED TO CONTINUE ITS DEVELOPMENT OF ROSGARD
    * PREPARING AN APPLICATION FOR START OF A PHASE 2 STUDY IN
SAME
INDICATION THAT IS PLANNED TO START AROUND TURN OF YEAR
2021/2022

Source text for Eikon:  ID:nMFN9qsWZg 
Further company coverage:  GUARD.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))